Circulating tumor cells: Liquid biopsy;Cellules tumorales circulantes: Biopsie liquide du cancer

Bulletin du Cancer

Volumn 101, Issue 1, 2014, Pages 17-23

  Alix Panabières, Catherine ^a,b   Pierga, Jean Yves ^c,d  

^a Laboratoire des Cellules Circulantes Rares Humaines (LCCRH)   (France)

^b UNIV MONTPELLIER   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Circulating tumor cells; Liquid biopsy; Prognosis; Solid tumors

Indexed keywords

CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MICROSCOPY; MULTICENTER STUDY (TOPIC); PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STRATIFICATION; TUMOR BIOPSY; TUMOR GROWTH; BIOPSY; CANCER STEM CELL; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LIQUID BIOPSY; METHODOLOGY; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SOLID TUMORS; TUMOR EMBOLISM;

CIRCULATING TUMOR CELLS; LIQUID BIOPSY; PROGNOSIS; SOLID TUMORS;

BIOPSY; CELL SEPARATION; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84896867301     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2014.1883     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 2011; 108: 12396-400.
3. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
4. Pantel K, Riethdorf S. Pathology: Are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol 2009; 6: 190-1.
5. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-56.
6. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-8.
7. Bidard FC, Saliba AE, Saias L, et al. Circulating tumor cells and breast cancer: detection techniques and clinical results. Bull Cancer 2009; 96: 73-86.
8. Lucci A, Hall CS, Lodhi AK, et al. Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 2012; 13: 688-95.
9. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004-10.
10. Rink M, Chun FK, Minner S, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int 2011; 107: 1668-75.
11. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-62.
12. Thompson EW, Haviv I. The social aspects of EMT-MET plasticity. Nat Med 2011; 17: 1048-9.
13. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012; 31: 673-87.
14. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
15. Bednarz N, Eltze E, Semjonow A, et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010; 16: 3340-8.
16. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelialmesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013; 73: 2059-69.
17. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-4.
18. Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-44.
19. Lianidou ES. Circulating tumor cells-new challenges ahead. Clin Chem 2012; 58: 805-7.
20. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010; 16: 398-406.
21. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-12.
22. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-45.
23. Ignatiadis M, Rothe F, Chaboteaux C, et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011; 6: e15624.
24. Fehm T, Muller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-12.
25. Georgoulias V, Bozionelou V, Agelaki S, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNApositive circulating tumor cells: results of a randomized phase II study. Ann Oncol 2012; 23: 1744-50.
26. Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013; 32: 179-88.
27. Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasisrelated biomarkers to the clinic-progress and pitfalls. Nat Rev Clin Oncol 2013; 10: 169-79.
28. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells. N Engl J Med 2008; 359: 366-77.
29. Ilie M, Long E, Butori C, et al. ALK-gene rearrangement: A comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012; 23: 2907-13.
30. Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013; 31: 2273-81.
31. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29: 1508-11.
32. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013; 10: 472-84.
33. Diaz Jr. LA,Williams RT,Wu J, Kinde I, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-40.